You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD1

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Tumors Trial in Guangzhou (Pemigatinib, PD-1 Inhibitors)

Recruiting
  • Carcinoma
  • +4 more
  • Guangzhou, Guangdong, China
    Lei Zhang
Jun 21, 2023

Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

Recruiting
  • Lung Cancer
  • Yiwu, Zhejiang, China
    The Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022

Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

Completed
  • Advanced Solid Tumor
  • Inosine 0.2g orally 3 times/day
  • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
  • Beijing, Beijing, China
    Qin li
Mar 30, 2023

Bevacizumab Combined With PD-1 Monoclonal Antibody in

Not yet recruiting
  • Colorectal Cancer
  • Bevacizumab Combined With PD-1 Monoclonal Antibody
  • (no location specified)
Nov 8, 2023

HNSCC, Radiotherapy, PD-1 Trial in Guangzhou (PD-1inhibitor, concurrent chemoradiotherapy)

Recruiting
  • HNSCC
  • +2 more
  • Guangzhou, Guangdong, China
    Sun yat-sen memorial hospital
Aug 6, 2023

Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)

Not yet recruiting
  • Stage IIIA Hepatocellular Carcinoma
  • Radiotherapy combined with TKI and Anti-PD-1 Antibody
  • (no location specified)
Sep 24, 2023

Esophageal Carcinoma, Neoadjuvant Immunotherapy Trial in Beijing (PD-1 blockade, Albumin paclitaxel, Carboplatin/Nedaplatin)

Recruiting
  • Esophageal Carcinoma
  • Neoadjuvant Immunotherapy
  • PD-1 blockade
  • +2 more
  • Beijing, Beijing, China
    Qin li
Mar 8, 2023

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus Trial in Beijing (L-DEP and PD-1 antibody)

Not yet recruiting
  • PD-1 Antibody
  • +3 more
  • L-DEP and PD-1 antibody
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Mar 8, 2023

Metastatic Melanoma, Advanced Melanoma Trial in San Francisco (XmAb22841, XmAb23104)

Not yet recruiting
  • Metastatic Melanoma
  • Advanced Melanoma
  • San Francisco, California
    University of California, San Francisco
Jan 13, 2023

Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
  • TACE
  • Nanjing, China
  • +1 more
Dec 28, 2022

Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
  • TACE
  • Nanjing, China
  • +1 more
Dec 28, 2022

Advanced NSCLC Trial in Shanghai (GLS-012+GLS-010, GLS-012+GLS-010+pemetrexed+carboplatin,

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shang Hai Pulmonary Hospital
Aug 3, 2023

NSCLC (NSCLC) Trial (Alirocumab and Cemiplimab)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Alirocumab and Cemiplimab
  • (no location specified)
Jan 31, 2023

HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With

Not yet recruiting
  • Gastric Cancer
  • Observational
  • (no location specified)
Dec 13, 2022

Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

Not yet recruiting
  • Muscle-Invasive Bladder Carcinoma
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center, Sun Yat-sen University
Aug 3, 2023

Colorectal Cancer Stage II, Colorectal Cancer Stage III, Mmr Deficiency Trial in Guangzhou (drug, radiation, procedure, other)

Active, not recruiting
  • Colorectal Cancer Stage II
  • Colorectal Cancer Stage III
  • Guangzhou, Guangdong, China
    Medical Oncology,Sun Yat-sen University Cancer Center
Jan 29, 2023

Advanced Lung Carcinoma Trial in Beijing (LK101 injection (personlized neoantigen pulsed DC vaccine ), Pembrolizumab,

Recruiting
  • Advanced Lung Carcinoma
  • LK101 injection (personlized neoantigen pulsed DC vaccine )
  • +2 more
  • Beijing, Beijing, China
    Cancer hospital Chinese Academy of Medical Sciences
May 23, 2023

Hepatocellular Carcinoma Trial in Beijing (iNKT Cells, PD-1, Regorafenib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • iNKT Cells
  • +2 more
  • Beijing, Beijing, China
    Beijing Youan Hospital,Capital Medical University
Jul 24, 2023

Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1 Trial in Changchun (nCRT ? (CapeOX+Sintilimab)×6 ?

Not yet recruiting
  • Locally Advanced Rectal Cancer
  • +2 more
  • nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W
  • Changchun, Ji Lin, China
    First Hospital of Jilin University
Aug 11, 2023

Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy Trial (neoadjuvant anti-PD-1 (Keytruda) plus chemo)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Neoadjuvant Chemoimmunotherapy
  • neoadjuvant anti-PD-1 (Keytruda) plus chemotherapy
  • (no location specified)
Feb 14, 2023

Advanced Breast Cancer, Breast Tumor Malignant Female Trial in Guangzhou (AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells)

Completed
  • Advanced Breast Cancer
  • Breast Neoplasm Malignant Female
  • AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Apr 11, 2023

Esophageal Tumor Metastatic, Esophageal Cancer Stage IVb Trial in Beijing (drug, biological, radiation)

Recruiting
  • Esophageal Neoplasm Metastatic
  • Esophageal Cancer Stage IVb
  • TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.
  • +3 more
  • Beijing, Beijing, China
    Cancer hospital, CAMS
Oct 19, 2023

Sintilimab in Combination With Chemoradiotherapy in High-risk

Recruiting
  • Nasopharyngeal Carcinoma
  • Sintilimab
  • Sintilimab (PD-1 Antibody)
  • Nanning, Guangxi, China
    Guangxi Medical University Cancer Hospital
Jan 29, 2023

Neoadjuvant Chemo, PD-1 Antibody, Radiotherapy Trial (neoadjuvant chemo combined with PD-1 antibody + radical radiotherapy)

Not yet recruiting
  • Neoadjuvant Chemotherapy
  • +3 more
  • neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy
  • (no location specified)
Sep 21, 2022